Navigation Links
Tengion Reports Fourth Quarter and Full Year 2011 Financial Results
Date:3/26/2012

WINSTON-SALEM, N.C., March 26, 2012/PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today reported its financial results for the year ended December 31, 2011 and provided a business and clinical update detailed in a separate press release issued today, in which the Company reported that it has made significant advances in its two lead programs.

"We have made significant progress advancing our Neo-Urinary Conduit and Neo-Kidney Augment programs and I believe we have created strong momentum to build upon as we continue to execute on our aggressive development goals in 2012," stated John L. Miclot, President and Chief Executive Officer of Tengion. "A fourth patient has now been enrolled and implanted in our Neo-Urinary Conduit clinical trial and we have submitted a pre-Investigational New Drug filing to FDA for our Neo-Kidney Augment one quarter ahead of schedule."

Financial UpdateFor the year ended December 31, 2011, the Company reported an adjusted net loss of $24.4 million, or $1.13 per basic and diluted common share, compared with an adjusted net loss of $25.8 million, or $2.80 per basic and diluted common share, for the same period in 2010.  

The decreased adjusted net loss for the 2011 period was primarily due to a decrease in interest expense of $1.2 million resulting from lower average debt balances outstanding in 2011, and a decrease in depreciation expense of $1.7 million resulting from both a change in the estimated useful life of leasehold improvements at the Company's leased facility in Winston-Salem, North Carolina and the impairment of the Company's leased facility in East Norriton, Pennsylvania.
These decreases were offset in part by increased general and administrative expense of $1.2 million related to restructuring charges incurred during 2011 and an increase in research and development expense of $0.4 m
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduitâ„¢ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduitâ„¢ in Bladder Cancer Patients
11. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "An Introduction to ... - November 2-3, 2015)" conference to their ... a comprehensive introduction to the regulations and requirements ... will be highly interactive, using real life examples ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... (Nasdaq:,CRYO), a medical device company focused on the treatment ... its pivotal,clinical study for the treatment of atrial fibrillation. ... said, "This is a,major milestone for CryoCor, being the ... for the use of ablation for the treatment of,atrial ...
... Novogen Limited,s subsidiary, Marshall Edwards Inc. (Nasdaq: MSHL ), has ... made the following ... Marshall Edwards, Inc. (Nasdaq: MSHL ) today announced enrolment of ... of,phenoxodiol in women with advanced ovarian cancer resistant or refractory,to platinum-based ...
Cached Medicine Technology:CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 2First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 4First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 5First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 6
(Date:9/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Melissa Memorial Hospital in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:9/3/2015)... ... , ... Dr. Robert Winchell has been appointed director of the Trauma Center ... Cornell Medical Center, effective July 27. He will serve on the faculty of Weill ... the critically injured and the development, design and operations of trauma systems. As chief, ...
(Date:9/3/2015)... Angeles, Ca (PRWEB) , ... September 03, 2015 , ... ... is a promising and convenient test that may help patients with oropharyngeal cancer (oral ... cases in the United States are often caused by HPV infections, which have a ...
(Date:9/3/2015)... ... ... Global Vision , the world leader in the development of innovative ... artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. , ... #F33 , Be the first to get a sneak peek of Intelligent Proofreading. Global ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more employers ... (1,000+ employees), according to data released from the 2014 United Benefit Advisors (UBA) ...
Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... Ben-Gurion University of the Negev researcher has achieved a ... mouse cells. "This study may open new therapeutic ... pre-pubertal cancer patients at risk of infertility due to ... in adult patients," explains Prof. Mahmoud Huleihel, of BGU,s ...
... Training basic surgical techniques on toy animals before having to ... anxious. At the same time, the use of laboratory animals ... from LIFE - the Faculty of Life Sciences at the ... known as the ,teddy laboratory, strengthens learning and the teaching ...
... Amanda Gardner HealthDay Reporter , MONDAY, Nov. 14 ... of the brain seem to be involved in "chemo brain," ... treatments for breast cancer. According to research in the ... areas of the brain that are involved in planning, attention ...
... 15 (HealthDay News) -- Brainy children are at increased risk ... study says. Researchers analyzed data from nearly 8,000 people ... education and socioeconomic status. The participants, IQ scores were checked ... illegal drugs (marijuana, cocaine, uppers, downers, LSD and heroin) was ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Nov. 15 ... to the statin drug Zocor (simvastatin) to help lower their ... Even though niacin appeared to increase HDL cholesterol -- ... fat in the blood, it did not reduce the risk ...
... breakthrough in understanding what stops a common form of skin ... available to the public in five years. ... Cancer Cell , an international team of scientists led ... University,s Department of Medicine at the Alfred Hospital, has discovered ...
Cached Medicine News:Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Breast Cancer Chemo Tied to Memory Troubles 2Health News:Breast Cancer Chemo Tied to Memory Troubles 3Health News:Smart Kids More Likely to Try Illicit Drugs as Young Adults 2Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3Health News:Stop signal discovered for skin cancer 2
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
For patient-friendly and safe capillary blood collection...
... a widely used screening test for determining ... oriented Dispette branded system is considered the ... stamp. No other system meets defined NCCLS/ICSH ... care. Specialized systems are also available for ...
Medicine Products: